Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-17 pm EDT			5-day change	1st Jan Change
6.82 ^USD	-0.87%		+5.57%	-40.38%

Jul. 01	Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) dropped from Russell 2000 Value-Defensive Index	CI
Jul. 01	Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) added to Russell 2000 Dynamic Index	CI

Tranche Update on Ironwood Pharmaceuticals, Inc.'s Equity Buyback Plan announced on May 6, 2021.

January 10, 2022 at 07:34 am EST

From October 1, 2021 to December 31, 2021, the company has repurchased 2,357,000 shares, representing 1.44% for $27.13 million. With this, the company has completed the repurchase of 2,357,000 shares, representing 1.44% for $27.13 million under the buyback announced on May 6, 2021.

Latest news about Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) dropped from Russell 2000 Value-Defensive Index	Jun. 30	CI
Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) added to Russell 2000 Dynamic Index	Jun. 30	CI
Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) dropped from Russell 2000 Growth-Defensive Index	Jun. 30	CI
Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) dropped from Russell 2000 Defensive Index	Jun. 30	CI
Ironwood Pharmaceuticals Names Sravan Emany to Additional Role of Chief Operating Officer	Jun. 21	MT
Ironwood Pharmaceuticals, Inc. Appoints Sravan K. Emany as Chief Operating Officer	Jun. 20	CI
Ironwood Pharmaceuticals Insider Sold Shares Worth $517,694, According to a Recent SEC Filing	Jun. 10	MT
Ironwood Pharmaceuticals Insider Sold Shares Worth $436,136, According to a Recent SEC Filing	May. 22	MT
Ironwood Pharmaceuticals, Inc. Presents Late-Breaking Data During the 2024 Digestive Disease Week Meeting from Its Pivotal Phase III Clinical Trial, STARS	May. 21	CI
Sector Update: Health Care Stocks Higher Late Afternoon	May. 09	MT
Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading	May. 09	MT
Sector Update: Health Care	May. 09	MT
Ironwood Pharmaceuticals' Shares Fall After Q1 Swings to a Non-GAAP Loss, Revenue Declines; 2024 Revenue Guidance Cut	May. 09	MT
Transcript : Ironwood Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
(IRWD) IRONWOOD PHARMACEUTICALS Expects Fiscal Year 2024 Revenue Range $405M - $425M	May. 09	MT
Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Reports Q1 Revenue $74.9M	May. 09	MT
Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024	May. 09	CI
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	Mar. 28	CI
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	Feb. 29	MT
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session	Feb. 29	MT
Top Premarket Decliners	Feb. 29	MT
Transcript : Ironwood Pharmaceuticals, Inc. - Special Call	Feb. 29
Ironwood says bowel disease treatment meets main goal in late-stage trial	Feb. 29	RE
Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $21 From $20, Maintains Overweight Rating	Feb. 16	MT

Chart Ironwood Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Ironwood Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.82 USD

Average target price

15.83 USD

Spread / Average Target

+132.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IRONWOOD PHARMACEUTICALS, INC.	-40.38%	1.09B
MODERNA, INC.	+24.74%	47.96B
IQVIA HOLDINGS INC.	-0.47%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	31.6B
ICON PUBLIC LIMITED COMPANY	+17.96%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.56B
MEDPACE HOLDINGS, INC.	+42.56%	14.14B
BIO-TECHNE CORPORATION	+1.46%	12.58B

Other Biotechnology & Medical Research